Petvivo Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Petvivo Holdings Inc (PETV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Petvivo Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 231,329M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+14.3% annualized vs trailing 12 months), vs holding steady (+1.2%) for its tracked peer group.
- Profitability: Its -478.1% net margin compares with 10.7% for the peer group.
- Scale: Petvivo Holdings Inc ranks #156 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Petvivo Holdings Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.05M compares with $1.11M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PETV Sales vs. its Competitors, Q1 2026
With a net margin of -478.09 %, Petvivo Holdings Inc reported lower profitability than its competitors (10.65 %).
Petvivo Holdings Inc generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
Petvivo Holdings Inc vs. its Competitors, Q1 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Petvivo Holdings Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Petvivo Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Petvivo Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Petvivo Holdings Inc's competitor groups requires a Commercial License.
Petvivo Holdings Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Petvivo Holdings Inc | No | Yes | Yes | No |
| Competitors combined (10) | ||||
| High-Confidence Competitors (9) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PETV Stock Performance relative to its Competitors
PETV Stock Performance relative to High-Confidence Competitors
PETV Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Merck and Co Inc | 282.9% | Outperformed |
| 2 | Eli Lilly And Company | 282.9% | Outperformed |
| 3 | Novartis Ag | 282.9% | Outperformed |
| 4 | Patterson Companies Inc | 282.9% | Outperformed |
| 5 | Elanco Animal Health Incorporated | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Petvivo Holdings Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Petvivo Holdings Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Petvivo Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Petvivo Holdings Inc |
21.49 | 1.18 |
 Eli Lilly And Company |
1,261,319.90 | 86,462.00 |
 Merck and Co Inc |
367,313.70 | 66,569.00 |
 Novartis Ag |
320,013.95 | 56,674.00 |
 Pfizer Inc |
168,101.73 | 63,625.00 |
 Sanofi |
58,975.87 | 49,307.90 |
| SUBTOTAL | 2,227,473.69 | 343,823.96 |
Sign in to see all competitors of Petvivo Holdings Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Petvivo Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Petvivo Holdings Inc's Competitors Named by the Company
Competitive relationships identified from Petvivo Holdings Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Zoetis, Inc. | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Novartis AG | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Bayer Animal Health | Company report | 85% |
| Elanco | Company report | 85% |
| NAH | Company report | 85% |
| Aratana Therapeutics | Company report | 85% |
| Ceva Animal Health | Company report | 85% |
| Merck & Co., Inc. | Company report | 85% |
| Vetoquinol | Company report | 85% |
| Boehringer Ingelheim Animal Health | Company report | 85% |
| Bayer AG | Company report | 85% |
| Dechra Pharmaceuticals PLC | Company report | 85% |
| Merial | Company report | 85% |
| Virbac Group | Company report | 85% |
| Boehringer Ingelheim GmbH | Company report | 85% |
| Kindred Bio | Company report | 85% |
| Medicines Co | Company report | 85% |
| Patterson Companies Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Petvivo Holdings Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Petvivo Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Zoetis Inc | United States 52.11 % |
| Elanco Animal Health Incorporated | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Petvivo Holdings Inc .
Petvivo Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Petvivo Holdings Inc | 21 | 53,712 | -444,387 |
| Eli Lilly And Company | 1,261,320 | 1,729,240 | 551,594 |
| Merck and Co Inc | 367,314 | 887,587 | 42,267 |
| Novartis Ag | 320,014 | 752,973 | 185,566 |
| Pfizer Inc | 168,102 | 848,333 | 54,160 |
| Sanofi | 58,976 | 21,607,316 | 3,889,794 |
| PEERS TOTAL | 2,227,452 | 1,109,850 | 193,720 |
Sign in to see all peers for Petvivo Holdings Inc .
Petvivo Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Elanco Animal Health Incorporated | Non-US 51.54 % |
| Patterson Companies Inc | United States 83.13 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Petvivo Holdings Inc .
Petvivo Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Petvivo Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Petvivo Holdings Inc ranks #156 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 607, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 164,558 | 13.47 % |
| 2 | Medtronic Plc | 132,095 | 10.81 % |
| 3 | Stryker Corp | 125,732 | 10.29 % |
| 4 | 3m Company | 98,540 | 8.06 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Medline Inc | 1,234 | 5.2% |
| 10 | Resmed Inc | 1,234 | 5.2% |
| 156 | Petvivo Holdings Inc | 21 | 0.00 % |
Market cap and industry share for the rest of Petvivo Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Petvivo Holdings Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 151 | Nexgel Inc | 33 | 39.66 % |
| 152 | Nexalin Technology Inc | 32 | 19.20 % |
| 153 | Milestone Scientific Inc | 28 | -19.49 % |
| 154 | Docgo Inc | 25 | -76.02 % |
| 155 | Vivos Inc | 1,234 | 12.3% |
| 156 | Petvivo Holdings Inc | 21 | - |
| 157 | Heartbeam Inc | 1,234 | 12.3% |
| 158 | Cvrx inc | 1,234 | 12.3% |
| 159 | Dariohealth Corp | 1,234 | 12.3% |
| 160 | Retractable Technologies Inc | 1,234 | 12.3% |
| 161 | Lifeward ltd | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Petvivo Holdings Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Petvivo Holdings Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.67 % | 46.20 % (avg) | -45.5 pp |
| Operating Margin | -7.46 % | industry median | -7.4 pp |
| EBITDA Margin | -6.68 % | -6.66 % (avg) | 0.0 pp |
| Capital Intensity (Capex / Revenue) | - | 7.13 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Petvivo Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 36.9x | - |
| EV / EBITDA | - | 17.8x | - |
| P/B | 9.7x | 4.6x | +5.1x |
| Return on Equity | -3.52 % | industry aggregate | -15.50 % |
| Return on Invested Capital | - | -6.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Petvivo Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | 171.25 % | 500.00 % | 23.50 % | -8.60 % | -17.24 % |
| Operating Margin | - | - | -8,983.70 % | -5,493.02 % | -965.91 % | - | - | - |
| Return on Invested Capital | -42.88 % | - | - | -48.24 % | -112.78 % | -336.51 % | -267.94 % | -96.87 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Petvivo Holdings Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Petvivo Holdings Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Petvivo Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 607 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Petvivo Holdings Inc's dedicated Suppliers and Customers pages, not here.
Petvivo Holdings Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Petvivo Holdings Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Petvivo Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+14.3% annualized vs trailing 12 months).
Weaknesses
- Operating margin 7.4 points below the industry median.
- Return on equity 15.5 points below the industry aggregate.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Petvivo Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Petvivo Holdings Inc | 0.17 | 1.31 | 0.09 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Sanofi | 0.27 | 1.09 | 0.20 |
Sign in to see all peers for Petvivo Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Petvivo Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Petvivo Holdings Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Sanofi | Q4 2025 | +10.9 % | +46.0 % |
| PEERS TOTAL | +11.5 % | -1.1 % |
Sign in to see all peers for Petvivo Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Petvivo Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Petvivo Holdings Inc | Q2 2026 | -45.5 % | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Sanofi | Q4 2025 | +9.3 % | - |
Sign in to see all peers for Petvivo Holdings Inc .
Petvivo Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Petvivo Holdings Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Sanofi | 5.96% | 8.19% | 10.55% |
Sign in to see all peers for Petvivo Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Petvivo Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Petvivo Holdings Inc | - | 18.19 |
| Eli Lilly And Company | 45.84 | 14.59 |
| Merck and Co Inc | 119.93 | 5.52 |
| Novartis Ag | 22.88 | 5.65 |
| Pfizer Inc | 41.60 | 2.64 |
| Sanofi | 7.55 | 1.20 |
| PEERS AVERAGE | 37.12 | 6.48 |
Sign in to see all peers for Petvivo Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.